Clarified Precision Medicine on Friday said that it has completed its acquisition of molecular diagnostics firm Interpares Biomedicine.

Biocept reported after the close of the market on Monday that its second quarter revenues increased dramatically year over year, as the cancer diagnostics firm continued its provision of COVID-19 testing.

DiaSorin said on Friday that its second quarter revenues rose 20 percent year over year, driven by strength in molecular diagnostic test sales.

BioMérieux said on Tuesday that its first quarter 2021 revenues grew approximately 10 percent year over year. The firm also lowered its full-year sales guidance due to uncertainties in the business environment.